

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

J. Barratt reports the following:

Employer: UNIVERSITY OF LEICESTER; Consultancy: Astellas, Alebund, Alnylam, Alpine, Argenx, BioCryst, Calliditas, Chinook, Dimerix, HiBio, Kira, Novartis, Omeros, Otsuka, Travers Therapeutics, Q32 Bio, Roche, Sanofi, Takeda, Vera Therapeutics, Vifor, Visterra; Research Funding: Novartis; GlaxoSmithKline; Calliditas, Visterra, Chinook, Omeros, Galapagos, argenx, Travers Therapeutics; and Advisory or Leadership Role: Editorial Board of Kidney International, CJASN, Glomerular Diseases & Clinical Science; Treasurer International IgA Nephropathy Network.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Jonathan Barratt

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results

Date of Completion: August 9, 2024

Disclosure Updated Date: March 21, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

J. Kristensen reports the following:

Consultancy: Calliditas Therapeutics AB

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Jens Kristensen

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results

Date of Completion: August 14, 2024

Disclosure Updated Date: August 14, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

R. Lafayette reports the following:

Employer: Stanford University; Consultancy: Calliditas, Inc; Chinook, Inc; Omeros, Inc; Otsuka, Inc. ; Alexion, Inc, Traveer, Inc., Vera, inc. , Novartis, Aurinia; Visterra, Alpine Bio, Beigene.; and Research Funding: NIH, Pfizer, Roche, Amgen, Otsuka, Omeros, Calliditas, Traveer, Apellis, Chinook, Vera, Beigene, .

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Richard A. Lafayette

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China

Date of Completion: August 7, 2024

Disclosure Updated Date: May 1, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

A. Stone reports the following:

Employer: Stone Biostatistics Ltd; Consultancy: Accession, Adaptimmune, Adcendo, Akamis, AstraZeneca, Biosight; Calliditas; Cogent, Confo, Crossbow, Dizal; GSK; GreyWolf, Intellia, Keros, Lava, Merus, OneCarbon, Orna, Purespring, Repare, Synklino, UroGen, VarmX; and Other Interests or Relationships: I serve, or have served on and IDMC in the last 24 months for the following companies. I wish to keep these confidential.; Achilles; Arrowhead, Autolus; Erytech; Canario Bio, PCI Biotech; OncoQuest; Sobi, Sotio; Trizell;

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Andrew M. Stone

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results

Date of Completion: August 12, 2024

Disclosure Updated Date: August 12, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

B. Wang reports the following:

Employer: Everest Medicines; and Ownership Interest: Everest Medicines.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Bei Wang

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results

Date of Completion: August 2, 2024

Disclosure Updated Date: August 2, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

L. Ying reports the following:

Employer: Everest Medicines; and Ownership Interest: Everest Medicines, Merck, BMS, etc.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Lisa H. Ying

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results

Date of Completion: August 2, 2024

Disclosure Updated Date: August 2, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

H. Zhang reports the following:

Employer: Peking University First Hospital; Consultancy: Calliditas; OMEROS; Chinook/Novartis, Ostuka, Roche, Vero, Alexion/AZ; and Advisory or Leadership Role: Calliditas; OMEROS; Chinook/Novartis, Ostuka, Roche, Vero, Alexion/AZ.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Hong Zhang

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results

Date of Completion: August 14, 2024

Disclosure Updated Date: June 18, 2024

ASN Journal Disclosure Form

As per ASN journal policy, I have disclosed any financial relationships or commitments I have held in the past 36 months as included below. I have listed my Current Employer below to indicate there is a relationship requiring disclosure. If no relationship exists, my Current Employer is not listed.

Z. Zhu reports the following:

Employer: Everest Medicines Limited; Bristol Myers Squibb; and Ownership Interest: Everest Medicines Limited; Bristol Myers Squibb.

I understand that the information above will be published within the journal article, if accepted, and that failure to comply and/or to accurately and completely report the potential financial conflicts of interest could lead to the following: 1) Prior to publication, article rejection, or 2) Post-publication, sanctions ranging from, but not limited to, issuing a correction, reporting the inaccurate information to the authors' institution, banning authors from submitting work to ASN journals for varying lengths of time, and/or retraction of the published work.

Name: Zhengying Zhu

Manuscript ID: K360-2024-000443R1

Manuscript Title: Efficacy and Safety of Nefecon in Patients With Immunoglobulin A Nephropathy From Mainland China: 2-Year NeflgArd Trial Results,

Date of Completion: September 12, 2024

Disclosure Updated Date: September 12, 2024